Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is undervalued on P/FCF.
Target Price
The average target price of DXB.AX is 0.84 and suggests 57% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell